FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952372767> ?p ?o ?g. }

• W2952372767 endingPage "276" @default.
• W2952372767 startingPage "275" @default.
• W2952372767 abstract "Background: Carfilzomib, lenalidomide and dexamethasone (KRd) has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. However, its effectiveness and safety profile in real clinical practice should be further assessed. Aims: We retrospectively evaluated 120 consecutive RRMM patients treated with KRd, in 9 hematology departments of Rete Ematologica Pugliese (REP), with the aim to evaluate the efficacy and safety with KRd treatment in a real world setting. Methods: Between December of 2015 and August 2018,120 RRMM patients were analyzed.The patients’ baseline characteristics are presented in Table 1. Median patient's age was 66 years and 41 patients(34%) were older than 70 years. The median number of previous treatment lines was 1 (range 1–11). The 94% of the patients had been already treated with bortezomib-based regimens and 33% with both lenalidomide- and bortezomib-based regimens. Moreover, half of the patients (52%) had a previous autologous stem cell transplant. The median time from the diagnosis to start of treatment with KRd was 40 months (range 5–295) and 30 patients were treated with KRd early (≤18 months from diagnosis).Disease status at the start of treatment with KRd was refractory in 33 patients(29%) and 13 patients(12%) were refractory to lenalidomide. Twenty-four patients(21%) were refractory at last therapy before KRd enrollment. Results: The overall response rate (ORR) was 84%(n = 93),with 23%(25) complete response (CR) and 50%(55) very good partial response(VGPR).The median duration of response was 12,9 months (range, 3,33–27,7). ORR was higher in patients relapsed after a previous autologous transplant (ASCT;56% vs 37% in those relapsed without prior ASCT;p 0,05).Patients treated in late relapse had a better ORR (44%) vs those in early relapse (19%; p 0,02). After a median follow-up of 13,4 months, median PFS was not reached (NR) and 2y-PFS was 61%, Figure 1. PFS was longer in responding patients (achieving at least PR) to those with less than PR (median PFS NR vs 4,9 months;p 0,0001).Median PFS in patients relapsed after a prior ASCT was NR vs 20 months in those without prior ASCT, (p 0,002).Patients achieving ASCT after KRD had a better PFS in confront to those without ASCT (median NR vs 9 months, p 0,001).Several baseline patient characteristics, such as the III ISS scoring, older age, prior exposure to lenalidomide and early relapse were found to negatively impact PFS.Twenty-eight patients(24%) performed 4 KRd cycles as bridge treatment to ASCT. The 64% of patients reached a VGPR and 67% received ASCT, with 9 upgraded from VGPR to complete response (CR) after ASCT.The treatment discontinuation rate due to adverse events (AEs) was 13%, most commonly related to lenalidomide(8%). KRd dose reduction was necessary in 11% of patients (2,5% for carfilzomib and 8% for lenalidomide).The most frequent AE was neutropenia(43%) and anemia (41%). Infections occurred in 10% of patients.Adverse Cardiovascular toxicity (Atrial fibrillation and pulmonary hypertension)occurred in 8% of patients.Summary/Conclusion: Our analysis confirmed that KRd is effective in RRMM patients. It is well tolerated and applicable to the majority of patients outside clinical trials. A longer PFS was shown in patients achieving at least a partial response (PR), relapsing after previous ASCT and in those with the possibility to perform ASCT after KRd treatment. Accordingly,KRd should be used as an optimal bridge regimen to ASCT. Previous ASCT should not hamper the option for KRd therapy." @default.
• W2952372767 created "2019-06-27" @default.
• W2952372767 creator A5000838879 @default.
• W2952372767 creator A5000873286 @default.
• W2952372767 creator A5003070018 @default.
• W2952372767 creator A5008194314 @default.
• W2952372767 creator A5010878192 @default.
• W2952372767 creator A5011614506 @default.
• W2952372767 creator A5015424111 @default.
• W2952372767 creator A5017640335 @default.
• W2952372767 creator A5020789491 @default.
• W2952372767 creator A5027397442 @default.
• W2952372767 creator A5028166248 @default.
• W2952372767 creator A5033896229 @default.
• W2952372767 creator A5038017063 @default.
• W2952372767 creator A5040546678 @default.
• W2952372767 creator A5044306304 @default.
• W2952372767 creator A5045407844 @default.
• W2952372767 creator A5047726764 @default.
• W2952372767 creator A5048142810 @default.
• W2952372767 creator A5054083067 @default.
• W2952372767 creator A5055843414 @default.
• W2952372767 creator A5057593886 @default.
• W2952372767 creator A5062380183 @default.
• W2952372767 creator A5064478569 @default.
• W2952372767 creator A5064660981 @default.
• W2952372767 creator A5069053301 @default.
• W2952372767 creator A5071675822 @default.
• W2952372767 creator A5072927664 @default.
• W2952372767 creator A5078063107 @default.
• W2952372767 creator A5083755644 @default.
• W2952372767 creator A5090237772 @default.
• W2952372767 date "2019-06-01" @default.
• W2952372767 modified "2023-09-27" @default.
• W2952372767 title "PF644 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)" @default.
• W2952372767 doi "https://doi.org/10.1097/01.hs9.0000560860.06450.b1" @default.
• W2952372767 hasPublicationYear "2019" @default.
• W2952372767 type Work @default.
• W2952372767 sameAs 2952372767 @default.
• W2952372767 citedByCount "0" @default.
• W2952372767 crossrefType "journal-article" @default.
• W2952372767 hasAuthorship W2952372767A5000838879 @default.
• W2952372767 hasAuthorship W2952372767A5000873286 @default.
• W2952372767 hasAuthorship W2952372767A5003070018 @default.
• W2952372767 hasAuthorship W2952372767A5008194314 @default.
• W2952372767 hasAuthorship W2952372767A5010878192 @default.
• W2952372767 hasAuthorship W2952372767A5011614506 @default.
• W2952372767 hasAuthorship W2952372767A5015424111 @default.
• W2952372767 hasAuthorship W2952372767A5017640335 @default.
• W2952372767 hasAuthorship W2952372767A5020789491 @default.
• W2952372767 hasAuthorship W2952372767A5027397442 @default.
• W2952372767 hasAuthorship W2952372767A5028166248 @default.
• W2952372767 hasAuthorship W2952372767A5033896229 @default.
• W2952372767 hasAuthorship W2952372767A5038017063 @default.
• W2952372767 hasAuthorship W2952372767A5040546678 @default.
• W2952372767 hasAuthorship W2952372767A5044306304 @default.
• W2952372767 hasAuthorship W2952372767A5045407844 @default.
• W2952372767 hasAuthorship W2952372767A5047726764 @default.
• W2952372767 hasAuthorship W2952372767A5048142810 @default.
• W2952372767 hasAuthorship W2952372767A5054083067 @default.
• W2952372767 hasAuthorship W2952372767A5055843414 @default.
• W2952372767 hasAuthorship W2952372767A5057593886 @default.
• W2952372767 hasAuthorship W2952372767A5062380183 @default.
• W2952372767 hasAuthorship W2952372767A5064478569 @default.
• W2952372767 hasAuthorship W2952372767A5064660981 @default.
• W2952372767 hasAuthorship W2952372767A5069053301 @default.
• W2952372767 hasAuthorship W2952372767A5071675822 @default.
• W2952372767 hasAuthorship W2952372767A5072927664 @default.
• W2952372767 hasAuthorship W2952372767A5078063107 @default.
• W2952372767 hasAuthorship W2952372767A5083755644 @default.
• W2952372767 hasAuthorship W2952372767A5090237772 @default.
• W2952372767 hasBestOaLocation W29523727671 @default.
• W2952372767 hasConcept C121332964 @default.
• W2952372767 hasConcept C126322002 @default.
• W2952372767 hasConcept C141071460 @default.
• W2952372767 hasConcept C142424586 @default.
• W2952372767 hasConcept C143998085 @default.
• W2952372767 hasConcept C2776063141 @default.
• W2952372767 hasConcept C2776364478 @default.
• W2952372767 hasConcept C2776694085 @default.
• W2952372767 hasConcept C2777478702 @default.
• W2952372767 hasConcept C2780108899 @default.
• W2952372767 hasConcept C2780401358 @default.
• W2952372767 hasConcept C2780775027 @default.
• W2952372767 hasConcept C71924100 @default.
• W2952372767 hasConcept C87355193 @default.
• W2952372767 hasConceptScore W2952372767C121332964 @default.
• W2952372767 hasConceptScore W2952372767C126322002 @default.
• W2952372767 hasConceptScore W2952372767C141071460 @default.
• W2952372767 hasConceptScore W2952372767C142424586 @default.
• W2952372767 hasConceptScore W2952372767C143998085 @default.
• W2952372767 hasConceptScore W2952372767C2776063141 @default.
• W2952372767 hasConceptScore W2952372767C2776364478 @default.
• W2952372767 hasConceptScore W2952372767C2776694085 @default.
• W2952372767 hasConceptScore W2952372767C2777478702 @default.
• W2952372767 hasConceptScore W2952372767C2780108899 @default.
• W2952372767 hasConceptScore W2952372767C2780401358 @default.
• W2952372767 hasConceptScore W2952372767C2780775027 @default.

• next